Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0163 | 0.053 | 0.1032 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0163 | 0.053 | 0.1032 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.0433 | 0.5393 | 0.5135 |
Brugia malayi | celfurPC protein | 0.0555 | 0.7602 | 0.4795 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.0418 | 0.5137 | 0.6515 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.0433 | 0.5393 | 0.6877 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.0689 | 1 | 1 |
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0256 | 0.2209 | 1 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0163 | 0.053 | 0.1032 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0418 | 0.5137 | 1 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0163 | 0.053 | 0.1032 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0418 | 0.5137 | 1 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0689 | 1 | 1 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.0418 | 0.5137 | 0.4865 |
Echinococcus granulosus | furin | 0.0689 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.027 | 0.2465 | 0.2043 |
Schistosoma mansoni | subfamily S8B non-peptidase homologue (S08 family) | 0.0163 | 0.053 | 0.053 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0163 | 0.053 | 0.1032 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0163 | 0.053 | 0.1032 |
Loa Loa (eye worm) | hypothetical protein | 0.0689 | 1 | 1 |
Echinococcus multilocularis | 0.0555 | 0.7602 | 1 | |
Schistosoma mansoni | furin-1 (S08 family) | 0.03 | 0.2995 | 0.2995 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 13.1154 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 56.2341 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 997 ] | ChEMBL. | No reference |
Potency (functional) | = 56.2341 um | PUBCHEM_BIOASSAY: qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease. (Class of assay: confirmatory) [Related pubchem assays: 1467, 2100, 2112, 1473, 1466 ] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.